Profile data is unavailable for this security.
About the company
Kyorin Pharmaceutical Co Ltd, formerly Kyorin Holdings Inc, is a Japan-based company mainly engaged in the pharmaceuticals business. The Pharmaceuticals segment is mainly engaged in the manufacture, purchase, sales and testing of pharmaceutical products, the purchase of raw materials for pharmaceuticals, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the operations related to clinical trials and information gathering such as searching for drug discovery seeds, as well as the drug candidate compound discovery research and compound evaluation business. The Company also conducts the diagnostic businesses and verifies and creates research targets that are directly linked to drug discovery.
- Revenue in JPY (TTM)119.73bn
- Net income in JPY4.82bn
- Incorporated1958
- Employees2.04k
- LocationKyorin Pharmaceutical Co Ltd8F-10F, Nikkei Bldg., 1-3-7, Ote-machiCHIYODA-KU 100-0004JapanJPN
- Phone+81 363749700
- Fax+81 335254780
- Websitehttps://www.kyorin-pharm.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASKA Pharmaceutical Holdings Co Ltd | 63.57bn | 5.98bn | 62.23bn | 762.00 | 9.65 | 0.8996 | 7.47 | 0.9789 | 210.94 | 210.94 | 2,243.73 | 2,263.17 | 0.7056 | 1.64 | 3.86 | 83,419,940.00 | 6.63 | 4.63 | 8.44 | 5.87 | 49.38 | 46.94 | 9.40 | 6.76 | 1.71 | -- | 0.1064 | 14.86 | 3.94 | 6.12 | 78.03 | 34.04 | -37.89 | 23.36 |
| Katakura Industries Co., Ltd. | 38.12bn | 2.89bn | 71.10bn | 1.04k | 22.96 | 0.8565 | 12.33 | 1.87 | 87.92 | 87.92 | 1,158.05 | 2,357.16 | 0.2725 | 1.99 | 5.37 | 36,650,960.00 | 2.17 | 2.35 | 2.79 | 3.34 | 38.62 | 37.75 | 7.97 | 8.32 | 2.56 | -- | 0.1026 | 18.81 | 16.62 | -2.04 | 8.09 | 18.87 | -7.46 | 10.76 |
| JCR Pharmaceuticals Co Ltd | 35.26bn | -437.00m | 90.26bn | 934.00 | -- | 1.54 | 28.87 | 2.56 | -3.49 | -3.49 | 281.91 | 451.84 | 0.338 | 0.4791 | 2.15 | 37,747,320.00 | -0.3864 | 8.66 | -0.5681 | 13.46 | 71.44 | 74.51 | -1.14 | 18.24 | 0.9827 | -0.3874 | 0.3325 | 30.60 | 24.83 | 13.11 | 46.00 | 8.19 | 18.54 | 21.67 |
| Kyorin Pharmaceutical Co Ltd | 119.73bn | 4.82bn | 96.33bn | 2.04k | 17.79 | 0.6588 | 10.42 | 0.8045 | 83.83 | 83.83 | 2,084.19 | 2,263.35 | 0.6745 | 1.21 | 3.18 | 58,635,650.00 | 2.71 | 3.05 | 3.36 | 3.79 | 42.87 | 47.11 | 4.02 | 4.76 | 1.74 | -- | 0.1593 | 67.74 | 5.53 | 1.02 | 12.68 | -4.98 | 7.41 | -7.06 |
| Nxera Pharma Co Ltd | 29.28bn | -3.71bn | 102.22bn | 350.00 | -- | 1.51 | 405.63 | 3.49 | -41.70 | -41.70 | 332.11 | 753.72 | 0.194 | 2.57 | 6.61 | 83,642,860.00 | -2.46 | -0.6588 | -2.76 | -0.7036 | 75.27 | 89.83 | -12.68 | -4.46 | 3.90 | -6.02 | 0.5060 | -- | -18.00 | -- | -1,982.98 | -- | -- | -- |
| Zeria Pharmaceutical Co Ltd | 81.47bn | 8.40bn | 117.98bn | 1.78k | 11.66 | 1.11 | 7.23 | 1.45 | 190.47 | 190.47 | 1,848.22 | 2,002.47 | 0.5316 | 1.50 | 3.60 | 45,846,530.00 | 5.49 | 3.89 | 8.46 | 6.28 | 72.99 | 71.93 | 10.33 | 7.57 | 0.9178 | -- | 0.3244 | 35.09 | 10.74 | 4.14 | 24.78 | 17.49 | 20.77 | 5.29 |
| Mochida Pharmaceutical Co Ltd | 104.51bn | 4.53bn | 124.40bn | 1.52k | 25.99 | 0.9116 | 16.74 | 1.19 | 127.75 | 127.75 | 2,945.16 | 3,641.81 | 0.6639 | 1.80 | 3.42 | 68,662,940.00 | 2.88 | 4.37 | 3.41 | 5.31 | 49.61 | 52.47 | 4.34 | 6.71 | 3.50 | -- | 0.00 | 45.16 | -0.3641 | -1.26 | -31.61 | -11.63 | 10.91 | -1.21 |
| Torii Pharmaceutical Co Ltd | 58.84bn | 5.28bn | 134.35bn | 583.00 | 24.85 | 1.09 | 23.58 | 2.28 | 187.71 | 187.71 | 2,093.33 | 4,271.84 | 0.4411 | 2.74 | 2.30 | 100,924,500.00 | 3.96 | 6.52 | 4.39 | 7.35 | 44.46 | 49.55 | 8.97 | 17.98 | 5.19 | -- | 0.00 | 24.17 | 11.74 | -2.67 | 4.44 | 28.76 | -20.38 | 20.11 |
Data as of Nov 22 2024. Currency figures normalised to Kyorin Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY
19.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Kopernik Global Investors LLCas of 15 Jul 2024 | 4.68m | 7.24% |
| Amundi Japan Ltd.as of 14 Nov 2024 | 1.83m | 2.84% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 1.35m | 2.10% |
| Nomura Asset Management Co., Ltd.as of 07 Nov 2024 | 1.35m | 2.08% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 823.80k | 1.28% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 692.21k | 1.07% |
| Nikko Asset Management Co., Ltd.as of 08 Nov 2024 | 635.90k | 0.98% |
| Daiwa Asset Management Co. Ltd.as of 31 Oct 2024 | 600.30k | 0.93% |
| Janus Henderson Investors (Singapore) Ltd.as of 30 Sep 2024 | 468.20k | 0.73% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 337.77k | 0.52% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
